Evidence method
Level · gp.fundamentals.debt_to_revenue
290.56% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TKO · Mar 31, 2026
TKO Group Holdings, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-208992General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
43.49% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
25.86% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
21.20% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
2.48% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History8 statesHistory building
Period transition
What moved in the state?
- Previous
- 79.45%
- Current
- 290.56%
- Delta
- 211.11%
- Previous
- 27.15%
- Current
- 43.49%
- Delta
- 16.34%
- Previous
- 68.85%
- Current
- 25.86%
- Delta
- -42.99%
- Previous
- 17.63%
- Current
- 21.20%
- Delta
- 3.56%
- Previous
- 2.48%
- Current
- 2.48%
- Delta
- -0.00%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Has State · TKO Group Holdings, Inc. →Transitioned To · TKO Fundamental State →Transitioned To · TKO BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · TKO CASH_GENERATION_INCREASED →Transitioned To · TKO GROWTH_DECREASED →Transitioned To · TKO PROFITABILITY_INCREASED →Transitioned To · TKO SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.